natgillin/translations-raw huggingface dataset:
When evaluated at 4 weeks postvaccination, the immunogenicity of the current refrigerator-stable formulation was shown to be similar to the immunogenicity of the earlier frozen formulation of ZOSTAVAX.
Ob vrednotenju štiri tedne po cepljenju se je pokazalo, da je imunogenost sedanje, v hladilniku stabilne oblike, podobna imunogenosti predhodne zamrznjene oblike cepiva ZOSTAVAX.
When EVICEL is applied during surgery, the surgeon must ensure that it is only applied onto the surface of tissue.
Ko kirurg uporabi zdravilo EVICEL med kirurškim posegom, mora paziti, da ga nanese samo na površino tkiva.
When Eviplera is co-administered with rifabutin, an additional 25 mg tablet of rilpivirine per day is recommended to be taken concomitantly with Eviplera, for the duration of the rifabutin co-administration.
Pri sočasnem dajanju zdravila Eviplera z rifabutinom se priporoča dodatna 25 mg tableta rilpivirina na dan, ki naj se jemlje sočasno z zdravilom Eviplera ves čas trajanja sočasne uporabe rifabutina.
When excessive dabigatran exposure is identified in patients at high risk of bleeding, a dose of 220 mg taken as one 110 mg capsule twice daily is recommended.
Če je izpostavljenost dabigatranu pri bolnikih z velikim tveganjem krvavitve povečana, je zanje priporočeni odmerek 220 mg, to je ena kapsula po 110 mg dvakrat na dan.
When exenatide was used in combination with metformin and/or a thiazolidinedione, no increase in the incidence of hypoglycaemia was observed over that of placebo in combination with metformin and/or a thiazolidinedione which may be due to this glucose-dependent insulinotropic mechanism (see section 4.4).
Ko so eksenatid uporabljali v kombinaciji z metforminom in/ali tiazolidindionom, niso opazili povečanja incidence hipoglikemije glede na placebo v kombinaciji z metforminom in/ali tiazolidindionom, kar je lahko zaradi tega od glukoze odvisnega insulinotropnega mehanizma (glejte poglavje 4.4).
When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.
Pri izpostavitvi kateremu koli od teh virusov pozneje v življenju se mačka ne bo okužila ali pa bo okužba blažja.
When exposed to IBR virus later in life, the calf will either not become infected or have a much less serious infection.
Če je tele IBR virusu izpostavljeno pozneje v življenju, se bodisi ne bo okužilo ali pa bo okužba pri njem mnogo manj resna.
When exposed to the virus later in life, the cat will either not become infected or have a much less serious infection.
Če je mačka virusu izpostavljena pozneje v življenju, se bodisi ne bo okužila ali pa bo okužba mnogo manj resna.
When Fampyra tablets are taken with food, the reduction in the area under the plasma concentration- time curve (AUC0-∞) of fampridine is approximately 2-7% (10 mg dose).
Pri uporabi tablet zdravila Fampyra s hrano je zmanjšanje površine pod krivuljo plazemske koncentracije v odvisnosti od časa (AUC0-∞) fampridina približno 2–7 % (10 mg odmerek).
When female rats were dosed 14days prior to mating and through to gestational day6, there was no effect on mating or on number of pregnant females.
Ko so podganje samice dobivale zdravilo 14 dni pred parjenjem in nato ves čas do 6. dne brejosti, ni bilo nikakršnega učinka na parjenje ali na število brejih samic.
When filling a new syringe, no large air bubbles should be left in either the syringe or the catheter.
Pri polnitvi nove brizge ne sme ne v brizgi ne v katetru ostati velikih zracnih mehurckov.
when fluticasone propionate is inhaled.
flutikazonpropionata je mogoče
when fluticasone propionate is inhaled.
pričakovati večje učinke.
When Forxiga was added to other antidiabetes medicines, Forxiga 10 mg decreased HbA1c levels by 0.54-0.68% more than placebo after 24 weeks.
Pri uporabi 10-miligramskega odmerka zdravila Forxiga v kombinaciji z drugimi antidiabetiki so se po 24 tednih ravni HbA1c zmanjšale za 0,54−0,68 % več kot pri placebu.
When Forxiga was used on its own at a dose of 10 mg, it decreased HbA1c levels by 0.66% more than placebo after 24 weeks.
10-miligramskega odmerka zdravila Forxiga kot samostojnega zdravila so se po 24 tednih ravni HbA1c zmanjšale za 0,66 % več kot pri placebu.
When Gazyvaro is given to patients with CLL or FL together with other medicines for cancer - this slows down the time it takes for their disease to get worse.
Ko zdravilo Gazyvaro uporabljajo bolniki s kronično limfocitno anemijo in folikularnim limfomom skupaj z drugimi zdravili za zdravljenje raka, to podaljša obdobje do poslabšanja bolezni.
When given 2 hours before CsA administration, sirolimus Cmax and AUC were not affected.
Uporaba sirolimusa 2 uri pred uporabo CsA ne vpliva na Cmax in AUC sirolimusa.
When given as a continuous infusion, stopping bleeding was assessed as ‘excellent’ in all 15 patients.
Pri dajanju zdravila v obliki kontinuirane infuzije je bila zaustavitev krvavitve ocenjena kot „odlična“ pri vseh 15 bolnikih.
When given as a drip (infusion) into your vein, Provenge works by teaching your immune cells to recognise and attack prostate cancer cells.
Ko zdravilo Provenge prejemate v obliki kapalne infuzije v žilo, zdravilo Provenge deluje tako, da nauči vaše imunske celice, da prepoznavajo in napadajo celice raka prostate.
When given as a single medicine or with FOLFIRI, the recommended dose of Cyramza is 8 mg per kg body weight given every two weeks.
Kadar se zdravilo Cyramza daje kot samostojno zdravilo ali skupaj s kemoterapijo FOLFIRI, je priporočeni odmerek 8 mg na kilogram telesne mase vsaka dva tedna.
When given as an injection under the skin, the recommended dose of Herceptin does not depend on the patient’s body weight and is 600 mg given over 2 to 5 minutes every three weeks.
Priporočeni odmerek zdravila Herceptin, ki se daje v obliki injekcije pod kožo, ni odvisen od telesne mase bolnika, ampak znaša 600 mg in se daje v trajanju 2 do 5 minut vsake tri tedne.
When given at the same time with other vaccines, Hexacima will be given at different injection sites.
Če se cepljenje opravlja sočasno z drugim cepivom bo cepivo Hexacima injicirano na različno mesto.
When given by infusion, the recommended dose is 8 mg per kilogram body weight once every 4 weeks, but doses above 800 mg per infusion are not recommended.
Priporočeni odmerek pri injiciranju v veno je 8 mg na kilogram telesne mase vsake štiri tedne, vendar odmerki nad 800 mg na infuzijo niso priporočeni.
When given concomitantly with other vaccines Bexsero must be administered at separate injection sites (see section 4.2).
Pri sočasnem cepljenju z drugimi cepivi morate za cepivo Bexsero izbrati ločeno mesto injiciranja (glejte poglavje 4.2).
When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m2 compared to
Pri dajanju v kombinaciji s cisplatinom (cisplatin 1. dan, topotekan od 1. do 5. dne) je bil 5. dan očistek topotekana v primerjavi s 1. dnem manjši (19,1 l/uro/m2 v primerjavi s 21,3 l/uro/m2
When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m2 compared to 21.3 l/h/m2 [n = 9]) (see section 4.5).
Pri dajanju v kombinaciji s cisplatinom (cisplatin 1. dan, topotekan od 1. do 5. dne) je bil 5. dan očistek topotekana v primerjavi s 1. dnem manjši (19,1 l/uro/m2 v primerjavi s 21,3 l/uro/m2 (n = 9)) (glejte poglavje 4.5).
When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m2 compared to 21.3 l/h/m2 [n = 9]) (see section 4.5).
Pri dajanju v kombinaciji s cisplatinom (cisplatin 1. dan, topotekan od 1. do 5. dne) je bil 5. dan očistek topotekana v primerjavi s 1. dnem manjši (19,1 l/uro/m2 v primerjavi s 21,3 l/uro/m2 [n = 9]) (glejte poglavje 4.5).
When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m2 compared to 21.3 l/h/m2 [n=9]) (see section 4.5).
Pri dajanju v kombinaciji s cisplatinom (cisplatin 1. dan, topotekan od 1. do 5. dne) je bil 5. dan očistek topotekana v primerjavi s 1. dnem manjši (19,1 l/uro/m2 v primerjavi s 21,3 l/uro/m2 [n = 9]) (glejte poglavje 4.5).
When given in combination with docetaxel, the recommended dose is 10 mg per kg body weight given on day 1 of a 21-day cycle, before being given the infusion of docetaxel.
Kadar se daje v kombinaciji z docetakselom, je priporočeni odmerek 10 mg na kilogram telesne mase, ki se daje 1. dan 21-dnevnega cikla, preden se infundira docetaksel.
When given in combination with paclitaxel, the recommended dose is 8 mg per kg body weight given on days 1 and 15 of a 28-day cycle, before being given the infusion of paclitaxel (which is given on days 1, 8 and 15).
Kadar se daje v kombinaciji s paklitakselom, je priporočeni odmerek 8 mg na kilogram telesne mase, ki se daje 1. in 15. dan 28-dnevnega cikla, preden se infundira paklitaksel (ki se daje 1., 8. in 15. dan).
When given on top of standard treatment or on top of placebo, Praluent produced a 24 to 36% greater reduction in blood levels of LDL-cholesterol than ezetimibe.
Ko so zdravilo Praluent dajali skupaj s standardnim zdravljenjem ali s placebom, so zabeležili za 24 do 36 % večje znižanje ravni holesterola LDL v krvi kot pri ezetimibu.
When given separately without the two other active substances, the bioavailability for levodopa is 15-33%, for carbidopa 40-70% and for entacapone 35% after a 200 mg oral dose.
Pri samostojni aplikaciji peroralnega odmerka 200 mg brez ostalih dveh zdravilnih učinkovin je bila biološka uporabnost levodope 15–33 %, karbidope 40–70 %, entakapona pa 35 %.
When given subcutaneously there were no effects at exposures 84-times greater than those at the maximum recommended human dose, based on AUC.
Med subkutano uporabo ob izpostavljenostih, 84-krat večjih od izpostavljenosti (na podlagi AUC) med uporabo največjega priporočenega odmerka za človeka, niso ugotovili vplivov.
When given to adults and adolescents, Invanz is given at a dose of 1 g once a day.
Odmerek zdravila Invanz za odrasle in mladostnike je 1 g enkrat dnevno.
When given to dogs at three to five times the recommended dose, injection site reactions, characterised by erythema and oedema occurred.
Pri dajanju tri- do štirikratnega priporočenega odmerka psom so se pojavile reakcije na mestu injiciranja kot eritem in edem.
When given to the mother, these antibodies are transferred from the mother to the piglets through the colostrum.
Kadar se cepivo injicira samici, se njena protitelesa prek kolostruma prenesejo na pujske.
When glucocorticoids (e.g. prednisone) and Oncaspar are given at the same time, alterations in coagulation parameters (e.g. fall in fibrinogen and Antithrombin III deficiency, ATIII) can be more pronounced.
Pri sočasni uporabi glukokortikoidov (npr. prednizona) in zdravila Oncaspar lahko spremembe v koagulacijskih parametrih (npr. padec ravni fibrinogena in pomanjkanje antitrombina III, ATIII) postanejo bolj izrazite.
When handling the pre-filled syringe, keep hands behind the needle.
Pri uporabi napolnjene brizge morate roki vedno držati zadaj za iglo.
When Harvoni is used in combination with ribavirin refer also to the Summary of
Če se zdravilo Harvoni uporablja v kombinaciji z ribavirinom, glejte tudi povzetek glavnih značilnosti za ribavirin za bolnike z očistkom kreatinina (CrCl-creatinine clearance)
When Harvoni is used in combination with ribavirin, extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients.
Pri uporabi zdravila Harvoni v kombinaciji z ribavirinom je potrebna izjemna previdnost, da se prepreči nosečnost bolnic in partnerk bolnikov.
When Hiprabovis IBR Marker Live is given to cattle, the animals’ immune systems recognise the viruses as ‘foreign’ and make defences against it.
Ko govedo cepimo, imunski sistem živali virus prepozna kot „tujek“ in proti njemu razvije obrambo.
When human insulin is inhaled, the onset of glucose lowering activity is within 10-20 minutes, the maximum effect is exerted approximately 2 hours after inhalation.
Po inhalaciji humanega insulina nastopi aktivnost zniževanja glukoze v 10-20 minutah, učinek je največji približno 2 uri po inhalaciji.
When iloprost at the concentration of 10 microgram/ml is administered via inhalation in patients with pulmonary hypertension or healthy volunteers (iloprost dose at the mouthpiece: 5 microgram: inhalation time in between 4.6 – 10.6 min), mean peak serum concentrations of about 100 to
Po inhaliranju iloprosta v koncentraciji 10 mikrogramov/ml pri bolnikih s pljučno hipertenzijo ali zdravih prostovoljcih (odmerek iloprosta v ustniku: 5 mikrogramov: inhalacijski čas je med 4,6 in
When imatinib is co-administered with other medicinal products, there is a potential for interactions.
Ob sočasni uporabi imatiniba z drugimi zdravili obstaja možnost njihovega medsebojnega delovanja.
When imatinib is co-administered with other medicinal products, there is a potential for medicinal product interactions Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides (see section 4.5).
Ob sočasni uporabi imatiniba z drugimi zdravili obstaja možnost njihovega medsebojnega delovanja.
When imatinib is co-administered with other medicinal products, there is a potential for medicinal product interactions.
Ob sočasni uporabi imatiniba z drugimi zdravili obstaja možnost njihovega medsebojnega delovanja.
When imiquimod is applied to the skin, it acts locally on the immune system to trigger the release of cytokines, including interferon.
Ko se imikvimod nanese na kožo, lokalno deluje na imunski sistem tako, da sproži sproščanje citokinov, vključno z interferonom.
When Improvac is given to male pigs it causes their immune systems to recognise the synthetic GnRF as ‘foreign’ and produce antibodies against it.
Kadar prašiči samci prejmejo zdravilo Improvac, njihov imunski sistem prepozna sintetični GnRF kot tuj, tako da začnejo proti njemu izdelovati protitelesa.
When in doubt, it is important to consult the nuclear medicine doctor who will supervise the procedure.
Če ste v dvomih je pomembno, da se posvetujete s svojim zdravnikom nuklearne medicine, ki nadzira postopek.
When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.
Če ste v dvomih je pomembno, da se posvetujete s svojim zdravnikom nuklearne medicine, ki nadzira postopek.
When in doubt, it is important to consult your nuclear medicine doctor who will supervise the procedure.
Če ste v dvomih, je pomembno, da se posvetujete z zdravnikom nuklearne medicine, ki bo postopek nadzoroval.
When in-use (in the pen), do not store in a refrigerator.
Med uporabo (v injekcijskem peresniku) ne shranjujte v hladilniku.
When increases in ALT levels are progressive despite dose reduction, or are accompanied by increased bilirubin or evidence of hepatic decompensation, therapy should be discontinued (see section 4.4).
Če so zvečanja koncentracij ALT progresivna kljub zmanjšanju odmerka ali če jih spremlja zvišan bilirubin ali znaki jetrne dekompenzacije, zdravljenje prekinemo (glejte poglavje 4.4).
When increasing the dosage, liver function tests should again be performed at the same frequency as when initiating treatment.
Ob povečanju odmerka je treba jetrne teste znova izvajati v enakih razmakih kot ob uvedbi zdravljenja.
When infused into a haemophilia patient, factor VIII binds to endogenous von Willebrand Factor in the patient’s circulation.
Po injiciranju bolniku s hemofilijo se faktor VIII veže na endogeni von Willebrandov faktor v bolnikovem krvnem obtoku.
When infused into a haemophilia patient, octocog alfa binds to endogenous von Willebrand Factor in the patient’s circulation.
Po injiciranju bolniku s hemofilijo se oktokog alfa veže na endogeni von Willebrandov faktor v bolnikovem krvnem obtoku.
When infused into a haemophiliac patient, factor VIII binds to the von Willebrand factor present in the patient’s circulation.
Faktor VIII se po infundiranju bolniku s hemofilijo veže na von Willebrandov faktor, prisoten v bolnikovi krvi.
When infused into a haemophiliac patient, factor VIII binds to von Willebrand factor in the patient’s circulation.
Po injiciranju faktorja VIII bolniku s hemofilijo se faktor VIII v krvnem obtoku veže na Willebrandov faktor.
When infused into a haemophiliac patient, factor VIII binds to vWF in the patient’s circulation.
Po injiciranju faktorja VIII bolniku s hemofilijo, se faktor VIII v krvnem obtoku veže na vWF.
When infused into a haemophiliac patient, FVIII binds to VWF in the patient’s circulation.
Če ga infundiramo hemofiliku, se v krvnem obtoku bolnika FVIII veže na VWF.
When infused into a haemophilic patient, factor VIII binds to vWF in the patient’s circulation.
Po infundiranjem bolniku s hemofilijo se faktor VIII v krvnem obtoku veže na vWF.
When infused into a haemophilic patient, factor VIII binds to vWF in the patient’s circulation.
Po infundiranju bolniku s hemofilijo se faktor VIII v krvnem obtoku veže na vWF.
When infused into a haemophilic patient, factor VIII binds to vWF in the patient’s circulation.
Po injiciranju faktorja VIII bolniku s hemofilijo se faktor VIII v krvnem obtoku veže na vWF.
When infused rapidly acute reactions associated with liposomal infusions have been reported.
Pri hitrem infundiranju so poročali o akutnih reakcijah, povezanih z liposomskimi infuzijami.
When inhaled it mainly attaches to the receptors in the airways and causes the muscles to relax, which keeps the airways open and helps with the patient’s breathing.
Ob vdihu se v glavnem veže na receptorje v dihalnih poteh in sprošča mišice, s čimer ohranja dihalne poti odprte in bolniku olajša dihanje.
When inhaled, this gas mixture can improve the flow of blood through the lungs, which may help to increase the amount of oxygen that reaches your baby’s blood.
Vdihavanje te mešanice plinov lahko izboljša pretok krvi skozi pljuča, kar pripomore k povečanju količine kisika, ki pride v dojenčkovo kri;
When inhaled, vilanterol reaches the receptors in the airways and activates them.
Ob inhalaciji vilanterol doseže receptorje v dihalnih poteh in jih aktivira.
When initiating Corbilta in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, the dosing of levodopa/benserazide should be discontinued in the previous night, and Corbilta should be started in the next morning.
Ko se zdravljenje z zdravilom Corbilta uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Corbilta.
When initiating Corbilta in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, thedosing of levodopa/benserazide should be discontinued in the previous night, and Corbilta should be started in the next morning.
Ko se zdravljenje z zdravilom Corbilta uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Corbilta.
When initiating Corbilta therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Corbilta 100 mg/25 mg/200 mg (or 50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or
Ob uvajanju terapije z zdravilom Corbilta pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Corbilta 100 mg/25 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali 75 mg/18,75 mg/200 mg ali 125 mg/31,25 mg/200 mg ali
When initiating Corbilta therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Corbilta 200 mg/50 mg/200 mg (or 50 mg/12.5 mg/200 mg or75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or
Ob uvajanju terapije z zdravilom Corbilta pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Corbilta 200 mg/50 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali 75 mg/18,75 mg/200 mg ali 100 mg/25 mg/200 mg ali
When initiating Corbilta therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Corbilta 50 mg/12.5 mg/200 mg (or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or
Ob uvajanju terapije z zdravilom Corbilta pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Corbilta 50 mg/12,5 mg/200 mg (ali 75 mg/18,75 mg/200 mg ali 100 mg/25 mg/200 mg ali 125 mg/31,25 mg/200 mg ali
When initiating Corbilta therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Corbilta 75 mg/18.75 mg/200 mg (or 50 mg/12.5 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or
Ob uvajanju terapije z zdravilom Corbilta pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Corbilta 75 mg/18,75 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali 100 mg/25 mg/200 mg ali 125 mg/31,25 mg/200 mg ali
When initiating Corbilta therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Corbilta, 125 mg/31.25 mg/200 mg (or
Ob uvajanju terapije z zdravilom Corbilta pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Corbilta
When initiating Eylea therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears.
Pri uvajanju zdravila Eylea je pri bolnikih s prisotnima navedenima dejavnikoma tveganja za zatrganje pigmentnega epitelija mrežnice, potrebna previdnost.
When initiating Levodopa/Carbidopa/Entacapone Orion in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, the dosing of levodopa/benserazide should be discontinued in the previous night, and Levodopa/Carbidopa/Entacapone Orion should be started in the next morning.
Ko se zdravljenje z zdravilom Levodopa/Carbidopa/Entacapone Orion uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Levodopa/Carbidopa/Entacapone Orion.
When initiating Levodopa/Carbidopa/Entacapone Orion in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, thedosing of levodopa/benserazide should be discontinued in the previous night, and Levodopa/Carbidopa/Entacapone Orion should be started in the next morning.
Ko se zdravljenje z zdravilom Levodopa/Carbidopa/Entacapone Orion uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Levodopa/Carbidopa/Entacapone Orion.
When initiating Levodopa/Carbidopa/Entacapone Orion therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg (or 50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or
Ob uvajanju terapije z zdravilom Levodopa/Carbidopa/Entacapone Orion pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg (ali 50 mg/12,5 mg/200 mg ali